Industry Symposia

Breakfast Symposium

Date: Monday 28th August 

Time: 7.00am to 8.00am (breakfast served from 6:45am)

Title: In Acromegaly, CONTROL IS CRITICAL

Content: Uncontrolled biochemical levels in acromegaly may increase mortality. 45% of patients treated with first generation SSAs remain uncontrolled. Next generation treatment options are now available that help achieve biochemical control and tumour volume shrinkage.         

Topic 1: Uncontrolled biochemical control in Acromegaly and associated co-morbidities
Topic 2: Signifor LAR (Pasreotide) in patients with inadequately controlled Acromegaly

Speakers: Professor Ken Ho and Dr Ann McCormack
Chair: TBC

This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.

This session is supported and organised byNovartis large  

 

Breakfast Symposium

Date: Tuesday 29th August 

Time: 7.00am to 8.00am (breakfast served from 6:45am)

Title: Somavert®(pegvisomant) – the role of a growth hormone receptor antagonist (GHRA) in uncontrolled acromegaly

Content:
- The clinical need for Somavert®( pegvisomant) in the Australian setting - Prof Ken Ho
- Describing the patient uncontrolled on SSA therapy who could be suitable for pegvisomant - Prof Marta Korbonits
- Demonstrate initiation and up-titration of pegvisomant - Prof Marta Korbonits
- Monitoring of patients while on pegvisomant, including LFTs, tumour size - Prof Marta Korbonits
- Patient outcomes on pegvisomant therapy - Prof Marta Korbonits

Topic 1: Clinical need for growth hormone receptor antagonist (GHRA) in Australia
Topic 2: Treatment of uncontrolled acromegaly with Somavert® (pegvisomant)

Speakers: Professor Ken Ho and Professor Marta Korbonits
Chair: Prof. Ken Ho

This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.

 This session is supported and organised byPfizer Endocrine Care1

 

 


Our Sponsors